Supplement reference
Huperzine A
A sourced reference on Huperzine A identity, evidence limits and safety context.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
What it is
Huperzine A is an alkaloid associated with Huperzia species and has cholinesterase-inhibiting activity. It is not simply a nutritional choline product.
Sources: National Library of Medicine, PubMed
What the cited evidence shows
A 2021 overview of systematic reviews found apparent cognitive and daily-living effects in Alzheimer disease studies, but high heterogeneity and low-quality primary evidence. It found little or no conclusion for mild cognitive impairment and insufficient evidence for wider outcomes.
Sources: National Library of Medicine, PubMed
Limits and safety context
This does not establish a general memory product or replace assessment of cognitive symptoms.
Sources: National Library of Medicine, PubMed
Published sources
- Huperzine A in dementia and mild cognitive impairment: overview of systematic reviews
National Library of Medicine, PubMed. 2021; accessed 6 September 2026.
Supports: Reviews found heterogeneity and low-quality primary evidence; not a basis for general memory claims.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.